Side-by-side · Research reference
BPC-157vsVIP
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2HUMAN-REVIEWED9/53 cited
BPhase 3HUMAN-REVIEWED9/42 cited
BPC-157
Stable Gastric Pentadecapeptide · Healing
SQ or IM · Local · Once or twice daily
VIP
Neuropeptide · VPAC1/VPAC2 Agonist · Emergency Use Authorization (COVID-19 ARDS)
IV infusion · Inhaled (investigational)Brown 2023Boesing 2022
01Mechanism of Action
Parameter
BPC-157
VIP
Primary target
VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2011Sikiric 2018
VPAC1 and VPAC2 G-protein-coupled receptorsUdupa 2025
Pathway
Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2011
VIP → VPAC1/VPAC2 activation → cAMP elevation → Pulmonary vasodilation + epithelial protection
Downstream effect
Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018
Anti-inflammatory cytokine modulation, alveolar-capillary membrane stabilization, pulmonary smooth muscle relaxation, reduced neutrophil infiltration
Feedback intact?
No known endogenous receptor; mechanism still under investigation
Yes — exogenous VIP acts as physiological agonist
Origin
Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018
Endogenous 28-amino-acid neuropeptide; synthetic analogue (aviptadil) identical to natural VIP
Antibody development
—
—
02Dosage Protocols
Parameter
BPC-157
VIP
Standard dose
250–500 mcg / dayHwang 2016
Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.
—
Frequency
Once or twice daily
Split dosing reported anecdotally for chronic injury.
—
Lower / starter dose
200 mcg / day
Conservative starter for new users.
—
Evidence basis
Animal-strong + Phase 2 clinicalSikiric 2018Hwang 2016
Phase 3 RCT (TESICO)Brown 2023
816-patient randomized controlled trial in COVID-19 ARDS.
Duration
2–4 weeks (acute injury); 4–8 weeks (chronic)
Anecdotal; no long-term human safety data.
—
Reconstitution
Bacteriostatic water, 1–2 mL
Lyophilized powder reconstituted with sterile diluent per protocol
Timing
Local SQ to injury site preferred (anecdotal)
Systemic SQ also used; oral bioavailability shown in animal studies.
—
Half-life
~30 min plasma (estimated)
Tissue half-life longer; mechanism may explain durable effect.
~2 minutes (plasma)
Rapid clearance necessitates continuous infusion.
Intravenous (ARDS protocol)
—
60–90 mcg/kg/day via continuous infusion
TESICO trial protocol for COVID-19 ARDS.
Inhaled (investigational)
—
Variable dosing under clinical trial protocolsBoesing 2022
Delivered via nebulizer for direct pulmonary deposition.
Treatment duration
—
3–14 days (acute ARDS)
04Side Effects & Safety
Parameter
BPC-157
VIP
Injection site reaction
Mild irritation (anecdotal)
—
GI symptoms
None reported in PL-14736 Phase 2
Nausea, diarrhea (VIP is endogenous GI peptide)
Cardiovascular
Not reported
—
Antibody formation
No data (no long-term human trials)
—
Pregnancy / OB
Avoid — insufficient safety data
—
Long-term safety
Unknown beyond Phase 2 trial duration
—
Drug interactions
None established
—
Hypotension
—
Transient vasodilation-related blood pressure drop
Tachycardia
—
Reflex tachycardia secondary to vasodilation
Infusion site reactions
—
Erythema, phlebitis (IV administration)
Overall tolerability
—
Well-tolerated in Phase 3 trials; adverse event profile comparable to placebo
Absolute Contraindications
BPC-157
- ·Pregnancy / breastfeeding
- ·Known active malignancy (theoretical VEGF concern)
VIP
- ·Known hypersensitivity to aviptadil or formulation components
Relative Contraindications
BPC-157
- ·History of cancer
- ·Concurrent VEGF inhibitor therapy (theoretical)
- ·Acute thrombotic events
VIP
- ·Severe hypotension or shock states (monitor blood pressure)
- ·Pregnancy — insufficient safety data
05Administration Protocol
Parameter
BPC-157
VIP
1. Reconstitution
Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.
Reconstitute lyophilized aviptadil powder with sterile diluent per manufacturer protocol. Inspect solution for particulates — should be clear and colorless.
2. Injection site
Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.
Administer as continuous 12-hour intravenous infusion via central or peripheral line. Use infusion pump for precise dosing (60–90 mcg/kg/day divided over infusion duration).
3. Timing
No strict timing requirement. Most users dose once or twice daily, often morning + evening.
Monitor blood pressure, heart rate, and oxygenation continuously during first infusion. Assess for hypotension and adjust infusion rate if needed.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.
Deliver via jet or mesh nebulizer per clinical trial protocol. Patient seated upright, normal tidal breathing for 10–15 minutes.
5. Needle
27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.
Store lyophilized powder at 2–8 °C, light-protected. Reconstituted solution: use immediately or within 24 hours if refrigerated.
06Stack Synergy
BPC-157
+ TB-500
StrongBPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.
- BPC-157
- 250–500 mcg SQ · daily
- TB-500
- 2 mg SQ · 2× per week
- Primary benefit
- Tendon/ligament/muscle repair via complementary angiogenesis + migration
VIP
— no documented stacks